{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:10:28Z","timestamp":1792044628378,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Collagen disorders encompass a wide range of genetic conditions caused by pathogenic variants in collagen genes for which there is an unmet need for treatments. They present various clinical features, ranging from localised tissue abnormalities to severe systemic complications. Symptoms differ significantly and depend on the pathogenic variant, which can affect various systems, including the musculoskeletal, cardiovascular, and respiratory systems, highlighting the complex implications of collagen gene pathogenic variants and the wide range of expression patterns among different collagen types. Gene-editing technologies, particularly Clustered Regularly Interspaced Palindromic Repeats (CRISPR)-Cas systems, have emerged as promising therapeutic options for these disorders, representing a putative one-for-all treatment strategy. This review provides an overview of current gene-editing strategies aimed at collagen-related diseases, including osteogenesis imperfecta, Alport syndrome, and dystrophic epidermolysis bullosa. We explore the application of CRISPR-Cas9, which facilitates targeted DNA modifications, base editing (BE), and prime editing (PE), enabling precise single-nucleotide alterations without double-strand breaks (DSB). Preclinical and clinical studies have shown the potential of gene therapy to enhance collagen production, restore tissue integrity, and alleviate symptoms. However, challenges persist, including the lack of recurring mutations, the need for improved delivery methods, the reduction of off-target effects, and the development of novel therapies. Despite these challenges, advancements in gene editing techniques appear promising in enhancing editing efficiency while minimising unintended mutations, paving the way for more precise and safer genetic interventions for collagen disorders. Gene editing is fundamentally transforming medicine and biotechnology. Its applications encompass advanced diagnostics, tailored therapeutic strategies, and solutions for rare genetic disorders. By enabling precise genetic modifications, gene editing is paving the way for treatments of previously untreatable diseases, including those linked to collagen pathogenic variants. This review discusses the latest advancements in gene therapy techniques targeting collagen-related disorders. It explores innovative approaches like CRISPR-Cas9-mediated gene editing and highlights emerging strategies, such as allele-specific inactivation and base editing (BE). By examining these cutting-edge therapies and their potential clinical applications, this review highlights the transformative impact of gene editing in treating collagen-related conditions, while also identifying critical challenges and future directions for research.<\/jats:p>","DOI":"10.1038\/s41434-025-00560-7","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:15:12Z","timestamp":1754910912000},"page":"676-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gene editing for collagen disorders: current advances and future perspectives"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-8937","authenticated-orcid":false,"given":"Klaudia","family":"Kocsy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6949-7380","authenticated-orcid":false,"given":"Harry","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Favour","family":"Felix-Ilemhenbhio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4282-449X","authenticated-orcid":false,"given":"Tom","family":"Van Agtmael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimoun","family":"Azzouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"560_CR1","doi-asserted-by":"crossref","unstructured":"Liu D, Nikoo M, Boran G, Zhou P, Regenstein J Collagen and gelatin. Annu Rev Food Sci Technol. 2015;6:527\u201357.","DOI":"10.1146\/annurev-food-031414-111800"},{"key":"560_CR2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-31566-z","volume":"13","author":"K Tarnutzer","year":"2023","unstructured":"Tarnutzer K, Siva Sankar D, Dengjel J, Ewald CY. Collagen constitutes about 12% in females and 17% in males of the total protein in mice. Sci Rep. 2023;13:4490.","journal-title":"Sci Rep"},{"key":"560_CR3","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.203950","volume":"131","author":"AL Fidler","year":"2018","unstructured":"Fidler AL, Boudko SP, Rokas A, Hudson BG. The triple helix of collagens \u2013 an ancient protein structure that enabled animal multicellularity and tissue evolution. J Cell Sci. 2018;131:jcs203950.","journal-title":"J Cell Sci"},{"key":"560_CR4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/10409238.2016.1269716","volume":"52","author":"RAF Gjaltema","year":"2017","unstructured":"Gjaltema RAF, Bank RA. Molecular insights into prolyl and lysyl hydroxylation of fibrillar collagens in health and disease. Crit Rev Biochem Mol Biol. 2017;52:74\u201395.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"560_CR5","doi-asserted-by":"crossref","unstructured":"Fujii KK, Taga Y, Takagi YK, Masuda R, Hattori S, Koide T The thermal stability of the collagen triple helix is tuned according to the environmental temperature. Int J Mol Sci [Internet]. 2022; 23:2040.","DOI":"10.3390\/ijms23042040"},{"key":"560_CR6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tig.2003.11.004","volume":"20","author":"J Myllyharju","year":"2004","unstructured":"Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004;20:33\u201343.","journal-title":"Trends Genet"},{"key":"560_CR7","doi-asserted-by":"crossref","unstructured":"Cao L, Zhang Z, Yuan D, Yu M, Min J Tissue engineering applications of recombinant human collagen: a review of recent progress. Front Bioeng Biotechnol. 2024;12:135846.","DOI":"10.3389\/fbioe.2024.1358246"},{"key":"560_CR8","doi-asserted-by":"crossref","unstructured":"Ricard-Blum S The Collagen Family. 2011;3:a004978.","DOI":"10.1101\/cshperspect.a004978"},{"key":"560_CR9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1146\/annurev.biochem.77.032207.120833","volume":"78","author":"MD Shoulders","year":"2009","unstructured":"Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929\u201358.","journal-title":"Annu Rev Biochem"},{"key":"560_CR10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/EBC20180071","volume":"63","author":"A Gatseva","year":"2019","unstructured":"Gatseva A, Sin YY, Brezzo G, Van Agtmael T. Basement membrane collagens and disease mechanisms. Essays Biochem. 2019;63:297\u2013312.","journal-title":"Essays Biochem"},{"key":"560_CR11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1242\/jcs.188672","volume":"129","author":"C Zeltz","year":"2016","unstructured":"Zeltz C, Gullberg D. The integrin\u2013collagen connection \u2013 a glue for tissue repair? J Cell Sci. 2016;129:653\u201364.","journal-title":"J Cell Sci"},{"key":"560_CR12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.25716","volume":"6","author":"V Juskaite","year":"2017","unstructured":"Juskaite V, Corcoran DS, Leitinger B. Collagen induces activation of DDR1 through lateral dimer association and phosphorylation between dimers. eLife. 2017;6:e25716.","journal-title":"eLife"},{"key":"560_CR13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.87037","volume":"12","author":"K Park","year":"2023","unstructured":"Park K, Jayadev R, Payne SG, Kenny-Ganzert IW, Chi Q, Costa DS, et al. Reciprocal discoidin domain receptor signaling strengthens integrin adhesion to connect adjacent tissues. eLife. 2023;12:RP87037.","journal-title":"eLife"},{"key":"560_CR14","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.836797","volume":"10","author":"CM Borza","year":"2022","unstructured":"Borza CM, Bolas G, Zhang X, Browning Monroe MB, Zhang M-Z, Meiler J, et al. The collagen receptor discoidin domain receptor 1b enhances integrin \u03b21-mediated cell migration by interacting with talin and promoting Rac1 activation. Front Cell Develop Biol. 2022;10. 836797.","journal-title":"Front Cell Develop Biol"},{"key":"560_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114240","volume":"185","author":"N Jariwala","year":"2022","unstructured":"Jariwala N, Ozols M, Bell M, Bradley E, Gilmore A, Debelle L, et al. Matrikines as mediators of tissue remodelling. Adv Drug Deliv Rev. 2022;185:114240.","journal-title":"Adv Drug Deliv Rev"},{"key":"560_CR16","first-page":"C633","volume":"325","author":"E Mavrogonatou","year":"2023","unstructured":"Mavrogonatou E, Papadopoulou A, Pratsinis H, Kletsas D. Senescence-associated alterations in the extracellular matrix: deciphering their role in the regulation of cellular function. Am J. 2023;325:C633\u2013C47.","journal-title":"Am J"},{"key":"560_CR17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.","journal-title":"Nat Commun"},{"key":"560_CR18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243\u201353.","journal-title":"EMBO Rep"},{"key":"560_CR19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","volume":"4","author":"T Stylianopoulos","year":"2018","unstructured":"Stylianopoulos T, Munn LL, Jain RK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends Cancer. 2018;4:292\u2013319.","journal-title":"Trends Cancer"},{"key":"560_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.matbio.2016.10.003","volume":"57-58","author":"M Jeanne","year":"2017","unstructured":"Jeanne M, Gould DB. Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations. Matrix Biol. 2017;57-58:29\u201344.","journal-title":"Matrix Biol"},{"key":"560_CR21","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/humu.22429","volume":"34","author":"RJ Butterfield","year":"2013","unstructured":"Butterfield RJ, Foley AR, Dastgir J, Asman S, Dunn DM, Zou Y, et al. Position of glycine substitutions in the triple helix of 61, 62, and 63 is correlated with severity and mode of inheritance in collagen VI myopathies. Hum Mutat. 2013;34:1558\u201367.","journal-title":"Hum Mutat"},{"key":"560_CR22","doi-asserted-by":"crossref","unstructured":"Sa\u0142aci\u0144ska K, Pinkier I, Rutkowska L, Chlebna-Sok\u00f3\u0142 D, Jakubowska-Pietkiewicz E, Micha\u0142us I, et al. Novel mutations within collagen Alpha1(I) and Alpha2(I) ligand-binding sites, broadening the spectrum of osteogenesis imperfecta \u2013 current insights into collagen Type I Lethal Regions. Front Genet. 2021;12:692978.","DOI":"10.3389\/fgene.2021.692978"},{"key":"560_CR23","volume":"11","author":"R Omar","year":"2025","unstructured":"Omar R, Lee MAW, Gonzalez-Trueba L, Thomson CR, Hansen U, Lianos S, et al. The chemical chaperone 4-phenylbutyric acid rescues molecular cell defects of COL3A1 mutations that cause vascular Ehlers Danlos syndrome. Cell Death Discov. 2025;11:200.","journal-title":"Cell Death Discov"},{"key":"560_CR24","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1172\/JCI93094","volume":"127","author":"LA Mullan","year":"2017","unstructured":"Mullan LA, Mularczyk EJ, Kung LH, Forouhan M, Wragg JMA, Goodacre R, et al. Increased intracellular proteolysis reduces disease severity in an ER stress\u2013associated dwarfism. J Clin Investig. 2017;127:3861\u20135.","journal-title":"J Clin Investig"},{"key":"560_CR25","doi-asserted-by":"crossref","unstructured":"Lamand\u00e9 SR Collagen VI Muscle disorders: mutation types, pathogenic mechanisms and approaches to therapy. In: Halper J, editor. Progress in Heritable Soft Connective Tissue Diseases. Springer International Publishing; 2021. p. 311\u201323.","DOI":"10.1007\/978-3-030-80614-9_14"},{"key":"560_CR26","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Bagci IS, Agostini B, Chen H, Feeney G, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387:2211\u20139.","journal-title":"N Engl J Med"},{"key":"560_CR27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823\u20136.","journal-title":"Science"},{"key":"560_CR28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816\u201321.","journal-title":"Science"},{"key":"560_CR29","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1093\/nar\/gkab686","volume":"49","author":"M Liu","year":"2021","unstructured":"Liu M, Zhang W, Xin C, Yin J, Shang Y, Ai C, et al. Global detection of DNA repair outcomes induced by CRISPR\u2013Cas9. Nucleic Acids Res. 2021;49:8732\u201342.","journal-title":"Nucleic Acids Res"},{"key":"560_CR30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420\u20134.","journal-title":"Nature"},{"key":"560_CR31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149\u201357.","journal-title":"Nature"},{"key":"560_CR32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","volume":"19","author":"EM Porto","year":"2020","unstructured":"Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov. 2020;19:839\u201359.","journal-title":"Nat Rev Drug Discov"},{"key":"560_CR33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ymthe.2004.05.016","volume":"10","author":"DT Woodley","year":"2004","unstructured":"Woodley DT, Keene DR, Atha T, Huang Y, Ram R, Kasahara N, et al. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther. 2004;10:318\u201326.","journal-title":"Mol Ther"},{"key":"560_CR34","doi-asserted-by":"crossref","unstructured":"Lwin SM, Syed F, Di WL, Kadiyirire T, Liu L, Guy A, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4:e126243.","DOI":"10.1016\/j.jid.2019.07.288"},{"key":"560_CR35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bone.2017.02.004","volume":"102","author":"J Lim","year":"2017","unstructured":"Lim J, Grafe I, Alexander S, Lee B. Genetic causes and mechanisms of osteogenesis imperfecta. Bone. 2017;102:40\u20139.","journal-title":"Bone"},{"key":"560_CR36","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.3390\/jcm10143141","volume":"10","author":"H Jung","year":"2021","unstructured":"Jung H, Rim YA, Park N, Nam Y, Ju JH. Restoration of osteogenesis by CRISPR\/Cas9 genome editing of the mutated COL1A1 gene in osteogenesis imperfecta. J Clin Med. 2021;10:3141.","journal-title":"J Clin Med"},{"key":"560_CR37","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1205122","volume":"11","author":"A Fus-Kujawa","year":"2023","unstructured":"Fus-Kujawa A, Mendrek B, Bajdak-Rusinek K, Diak N, Strzelec K, Gutmajster E, et al. Gene-repaired iPS cells as novel approach for patient with osteogenesis imperfecta. Front Bioeng Biotechnol. 2023;11:1205122.","journal-title":"Front Bioeng Biotechnol"},{"key":"560_CR38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jbmr.4783","volume":"38","author":"Y Cao","year":"2023","unstructured":"Cao Y, Li L, Ren X, Mao B, Yang Y, Mi H, et al. CRISPR\/Cas9 correction of a dominant cis-double-variant in COL1A1 isolated from a patient with osteogenesis imperfecta increases the osteogenic capacity of induced pluripotent stem cells. J Bone Miner Res. 2023;38:719\u201332.","journal-title":"J Bone Miner Res"},{"key":"560_CR39","doi-asserted-by":"crossref","unstructured":"Yang Y-S, Sato T, Chaugule S, Ma H, Xie J, Gao G, et al. AAV-based gene editing of type 1 collagen mutation to treat osteogenesis imperfecta. Mol Ther Nucleic Acids. 2024;35:102111.","DOI":"10.1016\/j.omtn.2023.102111"},{"key":"560_CR40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41572-020-0194-9","volume":"6","author":"F Malfait","year":"2020","unstructured":"Malfait F, Castori M, Francomano CA, Giunta C, Kosho T, Byers PH. The Ehlers\u2013Danlos syndromes. Nat Rev Dis Prim. 2020;6:64.","journal-title":"Nat Rev Dis Prim"},{"key":"560_CR41","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1172\/JCI22760","volume":"115","author":"RC Gensure","year":"2005","unstructured":"Gensure RC, M\u00e4kitie O, Barclay C, Chan C, DePalma SR, Bastepe M, et al. A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J Clin Investig. 2005;115:1250\u20137.","journal-title":"J Clin Investig"},{"key":"560_CR42","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/WNL.0b013e3181c3fd12","volume":"73","author":"S Alamowitch","year":"2009","unstructured":"Alamowitch S, Plaisier E, Favrole P, Prost C, Chen Z, Van Agtmael T, et al. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology. 2009;73:1873\u201382.","journal-title":"Neurology"},{"key":"560_CR43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.xkme.2020.05.014","volume":"2","author":"BA Warady","year":"2020","unstructured":"Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P, et al. Alport syndrome classification and management. Kidney Med. 2020;2:639\u201349.","journal-title":"Kidney Med"},{"key":"560_CR44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jmcb\/mju040","volume":"6","author":"J Xie","year":"2014","unstructured":"Xie J, Wu X, Ren H, Wang W, Wang Z, Pan X, et al. COL4A3 mutations cause focal segmental glomerulosclerosis. J Mol Cell Biol. 2014;6:498\u2013505.","journal-title":"J Mol Cell Biol"},{"key":"560_CR45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1523-1755.2004.00453.x","volume":"65","author":"YY Wang","year":"2004","unstructured":"Wang YY, Rana K, Tonna S, Lin T, Sin L, Savige J. <em>COL4A3<\/em> mutations and their clinical consequences in thin basement membrane nephropathy (TBMN)1. Kidney Int. 2004;65:786\u201390.","journal-title":"Kidney Int"},{"key":"560_CR46","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41431-019-0537-8","volume":"28","author":"S Daga","year":"2020","unstructured":"Daga S, Donati F, Capitani K, Croci S, Tita R, Giliberti A, et al. New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells. Eur J Hum Genet. 2020;28:480\u201390.","journal-title":"Eur J Hum Genet"},{"key":"560_CR47","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","volume":"93","author":"CE Kashtan","year":"2018","unstructured":"Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93:1045\u201351.","journal-title":"Kidney Int"},{"key":"560_CR48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jmg.2004.023754","volume":"42","author":"AK Lampe","year":"2005","unstructured":"Lampe AK, Dunn DM, von Niederhausern AC, Hamil C, Aoyagi A, Laval SH, et al. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy. J Med Genet. 2005;42:108.","journal-title":"J Med Genet"},{"key":"560_CR49","doi-asserted-by":"crossref","unstructured":"Benati D, Cattin E, Corradi F, Ferrari T, Pedrazzoli E, Patrizi C, et al. Restored collagen VI microfilaments network in the extracellular matrix of CRISPR-edited Ullrich congenital muscular dystrophy fibroblasts. Biomolecules. 2024;14:1412.","DOI":"10.3390\/biom14111412"},{"key":"560_CR50","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-M\u00e1rquez A, Mor\u00edn M, Fern\u00e1ndez-Pe\u00f1alver S, Badosa C, Hern\u00e1ndez-Delgado A, Natera-de Benito D, et al. CRISPR\/Cas9-mediated allele-specific disruption of a dominant COL6A1 pathogenic variant improves collagen VI network in patient fibroblasts. Int J Mol Sci [Internet]. 2022; 23:4410.","DOI":"10.3390\/ijms23084410"},{"key":"560_CR51","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.74","volume":"3","author":"V Bolduc","year":"2014","unstructured":"Bolduc V, Zou Y, Ko D, B\u00f6nnemann CG. siRNA-mediated Allele-specific silencing of a COL6A3 mutation in a cellular model of dominant ullrich muscular dystrophy. Mol Ther Nucleic Acids. 2014;3:e147.","journal-title":"Mol Ther Nucleic Acids"},{"key":"560_CR52","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.omtn.2017.07.006","volume":"8","author":"E Marrosu","year":"2017","unstructured":"Marrosu E, Ala P, Muntoni F, Zhou H. Gapmer antisense oligonucleotides suppress the mutant Allele of COL6A3 and restore functional protein in ullrich muscular dystrophy. Mol Ther Nucleic Acids. 2017;8:416\u201327.","journal-title":"Mol Ther Nucleic Acids"},{"key":"560_CR53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/1346-8138.14222","volume":"45","author":"M Watanabe","year":"2018","unstructured":"Watanabe M, Natsuga K, Shinkuma S, Shimizu H. Epidermal aspects of type VII collagen: Implications for dystrophic epidermolysis bullosa and epidermolysis bullosa acquisita. J Dermatol. 2018;45:515\u201321.","journal-title":"J Dermatol"},{"key":"560_CR54","doi-asserted-by":"crossref","unstructured":"Nystr\u00f6m A, Bruckner-Tuderman L, Kiritsi D Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers. Front Genet. 2021;12:737272.","DOI":"10.3389\/fgene.2021.737272"},{"key":"560_CR55","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","volume":"316","author":"Z Siprashvili","year":"2016","unstructured":"Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316:1808\u201317.","journal-title":"JAMA"},{"key":"560_CR56","volume":"17","author":"JY So","year":"2022","unstructured":"So JY, Nazaroff J, Iwummadu CV, Harris N, Gorell ES, Fulchand S, et al. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17:377.","journal-title":"Orphanet J Rare Dis"},{"key":"560_CR57","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.ymthe.2021.02.019","volume":"29","author":"J Bonafont","year":"2021","unstructured":"Bonafont J, Menc\u00eda A, Chac\u00f3n-Solano E, Srifa W, Vaidyanathan S, Romano R, et al. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. Mol Ther. 2021;29:2008\u201318.","journal-title":"Mol Ther"},{"key":"560_CR58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","volume":"12","author":"A Izmiryan","year":"2018","unstructured":"Izmiryan A, Ganier C, Bovolenta M, Schmitt A, Mavilio F, Hovnanian A. Ex Vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair. Mol Ther Nucleic Acids. 2018;12:554\u201367.","journal-title":"Mol Ther Nucleic Acids"},{"key":"560_CR59","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.ymthe.2022.06.005","volume":"30","author":"SA Hong","year":"2022","unstructured":"Hong SA, Kim SE, Lee AY, Hwang GH, Kim JH, Iwata H, et al. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa. Mol Ther. 2022;30:2664\u201379.","journal-title":"Mol Ther"},{"key":"560_CR60","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100191","volume":"3","author":"G Naso","year":"2023","unstructured":"Naso G, Gkazi SA, Georgiadis C, Jayarajan V, Jack\u00f3w J, Fleck R, et al. Cytosine deaminase base editing to restore COL7A1 in dystrophic epidermolysis bullosa human: murine skin model. JID Innov. 2023;3:100191.","journal-title":"JID Innov"},{"key":"560_CR61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24184-8","volume":"12","author":"A Sheriff","year":"2022","unstructured":"Sheriff A, Guri I, Zebrowska P, Llopis-Hernandez V, Brooks IR, Tekkela S, et al. ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation. Sci Rep. 2022;12:19643.","journal-title":"Sci Rep"},{"key":"560_CR62","doi-asserted-by":"crossref","unstructured":"Mustfa SA, Dimitrievska M, Wang C, Gu C, Sun N, Roma\u0144czuk K, et al. Porous silicon nanoneedles efficiently deliver adenine base editor to correct a recurrent pathogenic COL7A1 variant in recessive dystrophic epidermolysis bullosa. Adv Mater. 2025;37:2414728.","DOI":"10.1002\/adma.202414728"},{"key":"560_CR63","doi-asserted-by":"crossref","unstructured":"Petkovi\u0107 I, Bischof J, Kocher T, March OP, Liemberger B, Hainzl S, et al. COL17A1 editing via homology-directed repair in junctional epidermolysis bullosa. Frontiers in Medicine. 2022;9:976604.","DOI":"10.3389\/fmed.2022.976604"},{"key":"560_CR64","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1093\/nar\/gkad255","volume":"51","author":"A Carusillo","year":"2023","unstructured":"Carusillo A, Haider S, Sch\u00e4fer R, Rhiel M, T\u00fcrk D, Chmielewski Kay O, et al. A novel Cas9 fusion protein promotes targeted genome editing with reduced mutational burden in primary human cells. Nucleic Acids Res. 2023;51:4660\u201373.","journal-title":"Nucleic Acids Res"},{"key":"560_CR65","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11105-z","volume":"10","author":"TS Nambiar","year":"2019","unstructured":"Nambiar TS, Billon P, Diedenhofen G, Hayward SB, Taglialatela A, Cai K, et al. Stimulation of CRISPR-mediated homology-directed repair by an engineered RAD18 variant. Nat Commun. 2019;10:3395.","journal-title":"Nat Commun"},{"key":"560_CR66","doi-asserted-by":"crossref","unstructured":"Antoniou P, Miccio A, Brusson M Base and prime editing technologies for blood disorders. Front Genome Edit. 2021;3:618406.","DOI":"10.3389\/fgeed.2021.618406"},{"key":"560_CR67","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","volume":"6","author":"JR Davis","year":"2022","unstructured":"Davis JR, Wang X, Witte IP, Huang TP, Levy JM, Raguram A, et al. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng. 2022;6:1272\u201383.","journal-title":"Nat Biomed Eng"},{"key":"560_CR68","doi-asserted-by":"crossref","unstructured":"Hu Z, Wang Y, Liu Q, Qiu Y, Zhong Z, Li K, et al. Improving the precision of base editing by bubble hairpin single guide RNA. mBio. 2021;12:e00342.","DOI":"10.1128\/mBio.00342-21"},{"key":"560_CR69","doi-asserted-by":"crossref","unstructured":"C\u00f3cera-Ortega L and Wilders R and Kamps SC, Fabrizi B, Huber I, van der Made I et al. shRNAs targeting a common KCNQ1 variant could alleviate long-QT1 disease severity by inhibiting a mutant allele. Int J Mol Sci. 2022;23:4053.","DOI":"10.3390\/ijms23074053"},{"key":"560_CR70","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"560_CR71","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00439-023-02561-1","volume":"142","author":"JMT Hunt","year":"2023","unstructured":"Hunt JMT, Samson CA, Rand AD, Sheppard HM. Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum Genet. 2023;142:705\u201320.","journal-title":"Hum Genet"},{"key":"560_CR72","doi-asserted-by":"crossref","unstructured":"Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA Various AAV Serotypes and their applications in gene therapy: an overview. Cells [Internet]. 2023; 12:785.","DOI":"10.3390\/cells12050785"},{"key":"560_CR73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","volume":"30","author":"E Barbon","year":"2023","unstructured":"Barbon E, Kawecki C, Marmier S, Sakkal A, Collaud F, Charles S, et al. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Ther. 2023;30:245\u201354.","journal-title":"Gene Ther"},{"key":"560_CR74","first-page":"275ra20","volume":"7","author":"G Fredman","year":"2015","unstructured":"Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, Chiasson R, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med. 2015;7:275ra20\u2013ra20.","journal-title":"Sci Transl Med"},{"key":"560_CR75","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Shen J, Li D, Cheng Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing. Theranostics. 2021;11:614\u201348.","journal-title":"Theranostics"},{"key":"560_CR76","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jid.2023.10.035","volume":"144","author":"C Berthault","year":"2024","unstructured":"Berthault C, Gaucher S, Gouin O, Schmitt A, Chen M, Woodley D, et al. J Investig Dermatol. 2024;144:1322\u201333.","journal-title":"J Investig Dermatol"},{"key":"560_CR77","doi-asserted-by":"crossref","unstructured":"Wang X, Wang X, Li Y, A S, Qiu B, Bushmalyova A, et al. CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa. Mol Ther Methods Clin Develop. 2023;31:101304.","DOI":"10.1016\/j.omtm.2023.101134"},{"key":"560_CR78","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1126\/science.adp8179","volume":"386","author":"SR Lindley","year":"2024","unstructured":"Lindley SR, Subbaiah KCV, Priyanka F, Poosala P, Ma Y, Jalinous L, et al. Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies. Science. 2024;386:762\u20137.","journal-title":"Science"},{"key":"560_CR79","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","volume":"41","author":"MTN Yarnall","year":"2023","unstructured":"Yarnall MTN, Ioannidi EI, Schmitt-Ulms C, Krajeski RN, Lim J, Villiger L, et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat Biotechnol. 2023;41:500\u201312.","journal-title":"Nat Biotechnol"},{"key":"560_CR80","doi-asserted-by":"crossref","unstructured":"Bax BD, Sutormin D, McDonald NQ, Burley GA, Shelkovnikova T Oligonucleotide-Recognizing topoisomerase inhibitors (OTIs): precision gene editors for neurodegenerative diseases? Int J Mol Sci. 2022;23:11541.","DOI":"10.3390\/ijms231911541"},{"key":"560_CR81","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.1073\/pnas.92.18.8298","volume":"92","author":"TM Woolf","year":"1995","unstructured":"Woolf TM, Chase JM, Stinchcomb DT. Toward the therapeutic editing of mutated RNA sequences. PNAS. 1995;92:8298\u2013302.","journal-title":"PNAS"},{"key":"560_CR82","doi-asserted-by":"crossref","DOI":"10.1038\/srep41478","volume":"7","author":"M Fukuda","year":"2017","unstructured":"Fukuda M, Umeno H, Nose K, Nishitarumizu A, Noguchi R, Nakagawa H. Construction of a guide-RNA for site-directed RNA mutagenesis utilising intracellular A-to-I RNA editing. Sci Rep. 2017;7:41478.","journal-title":"Sci Rep"},{"key":"560_CR83","doi-asserted-by":"crossref","first-page":"18285","DOI":"10.1073\/pnas.1306243110","volume":"110","author":"MF Montiel-Gonzalez","year":"2013","unstructured":"Montiel-Gonzalez MF, Vallecillo-Viejo I, Yudowski GA, Rosenthal JJC. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc Natl Acad Sci USA. 2013;110:18285\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"560_CR84","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41587-023-01927-0","volume":"41","author":"LS Pfeiffer","year":"2023","unstructured":"Pfeiffer LS, Stafforst T. Precision RNA base editing with engineered and endogenous effectors. Nat Biotechnol. 2023;41:1526\u201342.","journal-title":"Nat Biotechnol"},{"key":"560_CR85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41587-019-0013-6","volume":"37","author":"T Merkle","year":"2019","unstructured":"Merkle T, Merz S, Reautschnig P, Blaha A, Li Q, Vogel P, et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat Biotechnol. 2019;37:133\u20138.","journal-title":"Nat Biotechnol"},{"key":"560_CR86","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","volume":"37","author":"L Qu","year":"2019","unstructured":"Qu L, Yi Z, Zhu S, Wang C, Cao Z, Zhou Z, et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat Biotechnol. 2019;37:1059\u201369.","journal-title":"Nat Biotechnol"},{"key":"560_CR87","doi-asserted-by":"crossref","unstructured":"Reautschnig P, Fruhner C, Wahn N, Wiegand CP, Kragness S, Yung JF, et al. Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA. Nat Biotechnol. 2024;43:545\u201357.","DOI":"10.1038\/s41587-024-02313-0"},{"key":"560_CR88","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/mt.2009.15","volume":"17","author":"FP Manfredsson","year":"2009","unstructured":"Manfredsson FP, Rising AC, Mandel RJ. AAV9: a potential blood-brain barrier buster. Mol Ther. 2009;17:403\u20135.","journal-title":"Mol Ther"},{"key":"560_CR89","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42386-0","volume":"14","author":"LM Riedmayr","year":"2023","unstructured":"Riedmayr LM, Hinrichsmeyer KS, Thalhammer SB, Mittas DM, Karguth N, Otify DY, et al. mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat Commun. 2023;14:6578.","journal-title":"Nat Commun"},{"key":"560_CR90","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/nar\/gky072","volume":"46","author":"L Infante Lara","year":"2018","unstructured":"Infante Lara L, Fenner S, Ratcliffe S, Isidro-Llobet A, Hann M, Bax B, et al. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences. Nucleic Acids Res. 2018;46:2218\u201333.","journal-title":"Nucleic Acids Res"},{"key":"560_CR91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/humu.22915","volume":"37","author":"M Barat-Houari","year":"2016","unstructured":"Barat-Houari M, Sarrabay G, Gatinois V, Fabre A, Dumont B, Genevieve D, et al. Mutation update for COL2A1 gene variants associated with type II collagenopathies. Hum Mutat. 2016;37:7\u201315.","journal-title":"Hum Mutat"},{"key":"560_CR92","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1086\/506478","volume":"79","author":"G Van Camp","year":"2006","unstructured":"Van Camp G, Snoeckx RL, Hilgert N, van den Ende J, Fukuoka H, Wagatsuma M, et al. A new autosomal recessive form of stickler syndrome is caused by a mutation in the <em>COL9A1<\/em> Gene. Am J Hum Genet. 2006;79:449\u201357.","journal-title":"Am J Hum Genet"},{"key":"560_CR93","volume":"12","author":"R Omar","year":"2021","unstructured":"Omar R, Malfait F, Van Agtmael T. Four decades in the making: collagen III and mechanisms of vascular Ehlers Danlos syndrome. Matrix Biol. 2021;12:100090.","journal-title":"Matrix Biol"},{"key":"560_CR94","doi-asserted-by":"crossref","unstructured":"Zhou X, Wang J, Mao J, Ye Q Clinical manifestations of alport syndrome-diffuse leiomyomatosis patients with contiguous gene deletions in COL4A6 and COL4A5. Front Med. 2021;8:766224.","DOI":"10.3389\/fmed.2021.766224"},{"key":"560_CR95","volume":"8","author":"X Liu","year":"2021","unstructured":"Liu X, Zheng T, Zhao C, Zhang Y, Liu H, Wang L, et al. Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy. Eye Vis. 2021;8:24.","journal-title":"Eye Vis"},{"key":"560_CR96","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/ar.24086","volume":"303","author":"SR Lamand\u00e9","year":"2020","unstructured":"Lamand\u00e9 SR, Bateman JF. Genetic disorders of the extracellular matrix. Anat Rec. 2020;303:1527\u201342.","journal-title":"Anat Rec"},{"key":"560_CR97","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/ajmg.a.61191","volume":"179","author":"TRW Nixon","year":"2019","unstructured":"Nixon TRW, Alexander P, Richards A, McNinch A, Bearcroft PWP, Cobben J, et al. Homozygous Type IX collagen variants (COL9A1, COL9A2, and COL9A3) causing recessive Stickler syndrome\u2014expanding the phenotype. Am J Med Genet Part A. 2019;179:1498\u2013506.","journal-title":"Am J Med Genet Part A"},{"key":"560_CR98","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/dvdy.221","volume":"250","author":"EP Dennis","year":"2021","unstructured":"Dennis EP, Greenhalgh-Maychell PL, Briggs MD. Multiple epiphyseal dysplasia and related disorders: Molecular genetics, disease mechanisms, and therapeutic avenues. Develop Dyn. 2021;250:345\u201359.","journal-title":"Develop Dyn"},{"key":"560_CR99","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/324023","volume":"69","author":"M Czarny-Ratajczak","year":"2001","unstructured":"Czarny-Ratajczak M, Lohiniva J, Rogala P, Kozlowski K, Per\u00e4l\u00e4 M, Carter L, et al. A mutation in COL9A1 causes multiple epiphyseal dysplasia: further evidence for locus heterogeneity. Am J Hum Genet. 2001;69:969\u201380.","journal-title":"Am J Hum Genet"},{"key":"560_CR100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/os.12382","volume":"10","author":"A Al Kaissi","year":"2018","unstructured":"Al Kaissi A, Ghachem MB, Nabil NM, Kenis V, Melchenko E, Morenko E, et al. Schmid\u2019s type of metaphyseal chondrodysplasia: diagnosis and management. Orthop Surg. 2018;10:241\u20136.","journal-title":"Orthop Surg"},{"key":"560_CR101","doi-asserted-by":"crossref","DOI":"10.1111\/nan.13004","volume":"50","author":"R El Sherif","year":"2024","unstructured":"El Sherif R, Saito Y, Hussein RS, Izu Y, Koch M, Noguchi S, et al. A novel homozygous nonsense variant in COL12A1 causes myopathic Ehlers-Danlos syndrome: a case report and literature review. Neuropathol Appl Neurobiol. 2024;50:e13004.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"560_CR102","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/brain\/awz107","volume":"142","author":"PM Rodr\u00edguez Cruz","year":"2019","unstructured":"Rodr\u00edguez Cruz PM, Cossins J, de Paula Estephan E, Munell F, Selby K, Hirano M, et al. The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations. Brain. 2019;142:1547\u201360.","journal-title":"Brain"},{"key":"560_CR103","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/humu.22764","volume":"36","author":"F Jonsson","year":"2015","unstructured":"Jonsson F, Bystr\u00f6m B, Davidson AE, Backman LJ, Kellgren TG, Tuft SJ, et al. Mutations in collagen, type XVII, Alpha 1 (COL17A1) cause epithelial recurrent erosion dystrophy (ERED). Hum Mutat. 2015;36:463\u201373.","journal-title":"Hum Mutat"},{"key":"560_CR104","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamaophthalmol.2016.1073","volume":"134","author":"S Hull","year":"2016","unstructured":"Hull S, Arno G, Ku CA, Ge Z, Waseem N, Chandra A, et al. Molecular and clinical findings in patients with Knobloch syndrome. JAMA Ophthalmol. 2016;134:753\u201362.","journal-title":"JAMA Ophthalmol"},{"key":"560_CR105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/humu.24333","volume":"43","author":"D Natera-de Benito","year":"2022","unstructured":"Natera-de Benito D, Jurgens JA, Yeung A, Zaharieva IT, Manzur A, DiTroia SP, et al. Recessive variants in COL25A1 gene as novel cause of arthrogryposis multiplex congenita with ocular congenital cranial dysinnervation disorder. Hum Mutat. 2022;43:487\u201398.","journal-title":"Hum Mutat"},{"key":"560_CR106","volume":"63","author":"K Evie","year":"2020","unstructured":"Evie K, Athina T, Nayia N, Angelos A, Ioannis P, Elisavet E, et al. First reported case of Steel syndrome in the European population: A novel homozygous mutation in COL27A1 and review of the literature. Eur J Med Genet. 2020;63:103939.","journal-title":"Eur J Med Genet"},{"key":"560_CR107","doi-asserted-by":"crossref","unstructured":"Holmes DF, Lu Y, Starborg T, Kadler KE Chapter Three - Collagen Fibril Assembly and Function. In: Litscher ES, Wassarman PM, editors. Curr Top Develop Biol. 130: Academic Press; 2018. p. 107\u201342.","DOI":"10.1016\/bs.ctdb.2018.02.004"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00560-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:39:00Z","timestamp":1766047140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00560-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00560-7","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"While preparing this work, the author(s) used Perplexity AI and Grammarly AI writing Assistance to correct grammar and increase readability. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies"}}]}}